Investorideas.com newswire, breaking biotechnology and pharma news

Tuesday, September 24, 2024

Seelos Therapeutics, Inc. (Nasdaq: SEEL) Soars on update for its SLS-002 (intranasal racemic ketamine) for PTSD

Seelos Therapeutics, Inc. (Nasdaq: SEEL) Soars on update for its SLS-002 (intranasal racemic ketamine) for PTSD: Seelos Therapeutics, Inc. (Nasdaq: SEEL) Soars on update for its SLS-002 (intranasal racemic ketamine) for PTSD

No comments:

Post a Comment